Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82673 | 0.78 | POLB (1.00) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL16346311 | 0.77 | POLB (0.43) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL16345809 | 0.76 | POLB (0.41) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL16346510 | 0.76 | ALDH1A1 (0.50) | POLBLMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28496721 | 0.75 | POLB (0.68) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL16948226 | 0.75 | POLB (0.40) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL21259220 | 0.74 | POLB (0.62) | POLBLMNAGAANSD2ABL1 | |
| SCHEMBL16345760 | 0.73 | LMNA (0.65) | POLBLMNAGAAHTTALDH1A1 | |
| SCHEMBL10188488 | 0.72 | POLB (0.64) | POLBLMNAGAANSD2ABL1 | |
| Glycerin SCHEMBL6953616 | 0.72 | POLB (0.80) | POLBLMNAGAANSD2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | claimed |
| EP-3016935-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-09-05 | — | — | EP | claimed |
| US-20180148412-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-05-31 | — | — | US | claimed |
| US-9963430-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2018-05-08 | — | — | US | claimed |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | claimed |
| EP-3016935-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | Hetero Research Foundation (IN) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | claimed |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | disclosed |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | disclosed |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
| EP-3016935-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-09-05 | — | — | EP | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| EP-3016935-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | Hetero Research Foundation (IN) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | POLB 73/4885LMNA 2182/4885GAA 505/4885 |
| US-20180148412-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | POLB 73/4885LMNA 2182/4885GAA 505/4885 |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | CYP3A5, CYP3A43, CYP3A4 | POLB 986/4885LMNA 2611/4885GAA 196/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | POLB 1264/4885LMNA 3050/4885GAA 231/4885 |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | CYP3A4, DHPS, MVD | POLB 73/4885LMNA 2182/4885GAA 505/4885 |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | POLB 1264/4885LMNA 3050/4885GAA 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.